- Photophobia drugs are used to treat sensitivity to light, a symptom commonly associated with conditions such as migraine, scleritis, corneal ulcers, conjunctivitis, and dry eyes. These drugs help manage pain, inflammation, and the neurological triggers of photophobia
- The demand for photophobia drugs is propelled by the rising incidence of migraine and ocular infections, greater diagnostic rates, and ongoing research into mechanism-specific treatments, including CGRP antagonists and serotonin receptor agonists
- North America is expected to lead the photophobia drug market due to high prevalence of migraines, well-established healthcare systems, and increased access to specialty medications
- Asia-Pacific is projected to be the fastest-growing region, driven by growing awareness, expansion of healthcare infrastructure, and increasing diagnosis of photophobia-related conditions
- The migraine segment is anticipated to dominate the market with a market share of 47.85% in 2024, as it is one of the most common and debilitating causes of photophobia. The availability of targeted therapies like triptans and CGRP antagonists continues to bolster market growth
